idarubicin has been researched along with mdv 3100 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, C; Li, B; Li, C; Li, J; Qi, Z; Wang, S; Wei, W; Xiao, S; Yan, S; Yang, K; Zhang, Y | 1 |
1 other study(ies) available for idarubicin and mdv 3100
| Article | Year |
|---|---|
Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein.
Topics: Docetaxel; Humans; Idarubicin; Male; Nitriles; Prostate; Prostatic Neoplasms, Castration-Resistant; Taxoids; Xeroderma Pigmentosum Group A Protein | 2022 |